Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
OPERATING EXPENSES:
Research and development	$ 15,362	$ 6,884
General and administrative	10,058	6,718
Total operating expenses	25,420	13,602
LOSS FROM OPERATIONS:	(25,420)	(13,602)
OTHER INCOME (EXPENSE), NET:
Other income	134	1
Foreign exchange gains (losses)	1,333	(643)
Benefit from R&D tax credit	2,922	1,557
Total other income, net	4,389	915
Loss before income taxes	(21,031)	(12,687)
Income tax expense	(140)	(28)
Net loss	(21,171)	(12,715)
Other comprehensive (loss) income:
Foreign exchange translation adjustment	(7,193)	1,988
Comprehensive loss	$ (28,364)	$ (10,727)
Net loss per share - basic (in dollars per share)	$ (0.50)	$ (0.35)
Net loss per share - diluted (in dollars per share)	$ (0.50)	$ (0.35)
Weighted average ordinary shares outstanding - basic (in shares)	42,036,563	36,569,290
Weighted average ordinary shares outstanding - diluted (in shares)	42,036,563	36,569,290